| Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. | |
| | |
MedLine Citation:
|
PMID: 16773275 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A recent meta-analysis of the Cholesterol Treatment Trialists' (CTT) Collaboration comes to the clear conclusion that a reduction in LDL-C using statins of 1 mmol/l (39 mg/dl) leads to a decrease in overall mortality by 12%, in coronary mortality by 19% and in the incidence of strokes by 17%, independent of the LDL-C level prior to the start of treatment. We conducted a systematic review retrieving 18 studies with a total of 116,343 [corrected] participants. Differences in average LDL-C reductions between the intervention and control groups during the follow-up and relative risks according to different clinical endpoints were extracted from the original publications. Metaregression analyses showed that reduction in LDL-C accounted for more than 75% of the variance in risk reductions for overall mortality and cardiovascular endpoints. On the basis of our estimates, a reduction in LDL-C of 1 mmol/l (39 mg/dl) leads to reductions in overall mortality, coronary mortality, incidence of non-fatal myocardial infarction, the combination of coronary mortality and non-fatal myocardial infarction, stroke and any vascular event by 15% (95% CI: 11-20%), 24% (95% CI: 20-28%), 27% (95% CI: 20-32%), 25% (95% CI: 22-29%), 24% (18-29%) and 22% (95% CI: 19-26%), respectively. We conclude that the extent to which statins lower LDL-C is strongly related to the improvement of clinical outcomes achieved by this class of drugs. |
| | |
Authors:
|
Bernd Genser; Winfried März |
Related Documents
:
|
12735555 - Radial artery use is safe in patients with moderate to severe left ventricular dysfunct... 10368115 - Comparing ami mortality among hospitals in patients 65 years of age and older: evaluati... 10803005 - Complications from cardiac catheterization: analysis of a military database. 12695455 - A single serum glucose measurement predicts adverse outcomes across the whole range of ... 10587695 - Analytic and clinical evaluation of the abbott axsym cardiac troponin i assay. 2969235 - Lipoprotein lp(a). a risk factor for myocardial infarction. |
Publication Detail:
|
Type: Journal Article; Meta-Analysis; Review Date: 2006-06-20 |
Journal Detail:
|
Title: Clinical research in cardiology : official journal of the German Cardiac Society Volume: 95 ISSN: 1861-0684 ISO Abbreviation: - Publication Date: 2006 Aug |
Date Detail:
|
Created Date: 2006-07-26 Completed Date: 2007-04-03 Revised Date: 2007-10-26 |
Medline Journal Info:
|
Nlm Unique ID: 101264123 Medline TA: Clin Res Cardiol Country: Germany |
Other Details:
|
Languages: eng Pagination: 393-404 Citation Subset: IM |
Affiliation:
|
BGStats Consulting, Hochstrasse 7, 8071, Graz, Austria. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cardiovascular Diseases*
/
blood,
drug therapy,
epidemiology Cholesterol, LDL / blood*, drug effects Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Incidence Prognosis Risk Factors Survival Rate |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| Comments/Corrections | |
Erratum In:
|
Clin Res Cardiol. 2007 Jul;96(7):526 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Follow-up of a large population of asymptomatic/oligosymptomatic hyperckemic subjects.
Next Document: Evaluation of morphological and molecular variation in Plantago asiatica var. densiuscula, with spec...